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After several decades of epidemiological and laboratory
research, how well do we understand the role of endoge-
nous hormones in the aetiology of breast cancer? Early
studies showed that risk varies with several hormonal
events: risk is increased by early menarche and late
menopause, and decreased by giving birth at a young age
and by high parity. The protective effect of pregnancy is
probably due to hormonally induced differentiation of
breast epithelial cells, causing a reduction in the number
of susceptible cells. The effects of age at menarche and
menopause indicate that the duration of exposure to cyclic
ovarian function is an important determinant of breast
cancer risk, but it has proved difficult to establish whether
oestradiol and/or progesterone is responsible, or to show
whether variations in hormone levels between women
have any important effect on risk.
Most of the early epidemiological studies of endogenous
hormones and breast cancer sought to test the simple
hypothesis that high oestrogen levels would increase risk.
The first studies used a case–control design; hormone
levels in women with breast cancer were compared with
those in women without breast cancer. This design is rela-
tively fast and cheap, but interpretation is limited by the
possibility that any differences observed could be caused
by the tumour or by the treatment, rather than being
markers of a long-standing hormonal environment that has
led to the development of the disease. To avoid this
problem it is necessary to conduct prospective studies in
which samples are collected from many thousands of
healthy women who are followed for the occurrence of
breast cancer; hormone levels are then measured in the
stored samples from women who develop breast cancer
and compared with measurements from women who
remain free of breast cancer. These prospective studies
are slow and expensive to conduct, but during the past
few years several have matured and important results have
been published on endogenous hormones and breast
cancer risk in postmenopausal women.
Figure 1 shows the current summary of these prospective
data for oestradiol in postmenopausal women [1–8]. For
each study, we have plotted the most adjusted estimate of
relative risk of breast cancer for women with high levels of
oestradiol in that study compared with women with low
oestradiol, together with a weighted average of the results
Figure 1
Prospective studies of oestradiol and breast cancer risk in
postmenopausal women. For each study, the relative risk plotted is for
women with the highest oestradiol concentration (tertile or quartile)
compared with women with the lowest concentration. The ‘all studies’
estimate was calculated by weighting the individual relative risks by the
inverse of their estimated variances, on a logarithmic scale. The relative
risk for the study by Garland et al 1992 [1] was calculated by us from
published data.
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from all the studies. Seven out of eight studies found
increased relative risks in association with high levels of
oestradiol, and the pooled relative risk is 2.3 (95% confi-
dence interval 1.6–3.2). Thus, the data strongly support the
hypothesis that high levels of oestradiol in postmenopausal
women increase breast cancer risk. The studies that have
measured bioavailable oestradiol and/or oestrone as well as
total oestradiol have resulted in broadly similar risk esti-
mates for these different measurements (not shown). This
would be expected because bioavailable oestradiol is very
strongly correlated with total oestradiol in postmenopausal
women. Likewise, serum oestrone is the main precursor of
oestradiol in postmenopausal women, and thus the two
hormones are strongly correlated with each other.
For premenopausal women, data on oestradiol and breast
cancer risk have been published from only four prospective
studies [2,9–11] with a total of 179 cases of breast cancer.
The numbers for progesterone are even smaller; data have
been published from three studies [2,9,11] with a total of
only 99 cases. None of these studies found statistically sig-
nificant associations between oestradiol or progesterone
and breast cancer risk. However, the design and interpreta-
tion of these studies is complicated by the large physiologi-
cal variations in serum concentrations of both oestradiol
and progesterone during the menstrual cycle. In a study of
the repeatability of serum hormone levels, Muti et al [12]
took two samples 1year apart from 60 premenopausal
women, attempting to collect the two samples under iden-
tical conditions on the same day of the luteal phase of the
menstrual cycle; correlations between the two samples
were high for androgens and peptide hormones, but very
low for oestradiol. This suggests that more than one sample
is needed to estimate a woman’s oestradiol level in the
luteal phase of the menstrual cycle reliably. Furthermore,
oestradiol levels during the mid-cycle peak [11], or cumu-
lative exposure to oestradiol over the entire cycle, may be
of importance in relation to breast cancer risk. Future
studies should ideally collect several samples from each
woman and from each of at least two menstrual cycles.
In addition to the observational epidemiological studies of
endogenous hormones and breast cancer risk, recently
published trials of the preventive effects of selective
oestrogen receptor modulators have provided important
further evidence for the role of oestradiol in the aetiology
of breast cancer. The first trials [13] have suggested that
both tamoxifen and raloxifene may reduce breast cancer
rates. Much more information is needed to substantiate
these findings and to study the effects of these drugs on
breast cancer mortality, but these early results do imply
that blocking the action of oestrogens can reduce the inci-
dence of breast cancer.
What about other hormones such as androgens, insulin-
like growth factor-I and prolactin? Unlike oestradiol,
serum concentrations of these hormones do not change
dramatically at menopause, and the strong protective
effect of early menopause is likely to be due to changes in
oestradiol (and possibly progesterone) rather than changes
in androgens or peptide hormones. The recent prospec-
tive studies have reported that, like oestradiol, serum
concentrations of testosterone, androstenedione and
dehydroepiandrosterone are positively associated with
breast cancer risk in postmenopausal women [4–8,14–16].
These sex hormones are all products of the same meta-
bolic pathway and their serum concentrations are posi-
tively correlated with each other. Multivariate analyses of
the existing studies have not produced a consistent con-
clusion as to which steroid hormone is most closely related
to risk. More data should help, but the results will require
cautious interpretation because the measurements for dif-
ferent hormones are not equally informative. For example,
in postmenopausal women the reproducibility of measure-
ments has been found to be higher for testosterone than
for oestradiol [17]; this could result in testosterone being
apparently more strongly associated with risk than oestra-
diol simply because the measurement for testosterone is
more informative.
As well as the steroid hormones, recent prospective
studies [18,19] have suggested that the peptide hormones
insulin-like growth factor-I (in premenopausal women)
and prolactin (in postmenopausal women) may also be
related to breast cancer risk. The metabolism of these
peptides has links to the metabolism of sex hormones, but
the serum concentrations of these hormones are not
strongly correlated with oestrogens and their effects on
breast cancer could well be independent.
The most likely mechanism by which oestradiol and
perhaps other hormones affect breast cancer risk is by
controlling the mitotic rate of the breast epithelial cells.
High mitotic rates can increase cancer risk by increasing
the chance of mutations occurring and of being repli-
cated before they are repaired, and can also increase the
growth of early tumours [20]. Studies of the mitotic rate
in the breast epithelial cells of premenopausal women
[21] have shown that some mitoses occur throughout the
menstrual cycle, but that there is a peak in activity
during the mid-to-late luteal phase when serum concen-
trations of both oestradiol and progesterone are high.
Experiments using human breast tissue grafted into mice
[22,23] show that oestradiol is a mitogen. No mitogenic
effect was seen in human breast tissue in mice after
administration of progesterone [23], but this does not
exclude the possibility of a mitogenic effect under physi-
ological conditions in women [24]. These data imply that
oestradiol alone may increase breast cancer risk through
the stimulation of mitosis, but it remains possible that, in
premenopausal women, progesterone may augment this
effect of oestradiol.Breast Cancer Research    Vol 1 No 1 Key and Verkasalo
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In addition to stimulating mitosis, it has been suggested
that oestradiol could also increase breast cancer risk
because some of its metabolites such as the catechol
oestrogen 4-hydroxyoestradiol might cause direct DNA
damage through the formation of free radicals [25,26].
Much of the experimental evidence for this hypothesis is
derived from studies on kidney cancer in hamsters, which
may well behave differently from human breast cancer.
Early reports that women with genetically determined
reduced inactivation of catechol oestrogens are at increased
risk of breast cancer have not been confirmed [27]. More
data are needed before this hypothesis can be evaluated.
Mutations in high-risk genes such as BRCA1 increase the
risk for several hormone-related cancers. The mechanisms
for these effects may include interactions with oestrogen
as well as direct effects on cell proliferation and apoptosis;
for example, wild-type BRCA1 may suppress oestrogen-
dependent transcription [28]. Inherited mutations in high-
risk genes are involved in only a small proportion of breast
cancers, but a substantial component of breast cancer risk
may be determined by the sum of multiple smaller
genetic effects. Recent twin studies on breast cancer
[29,30], which account for all modes of genetic transmis-
sion, indicate that hereditary genetic factors may con-
tribute to as much one-third of the variation in breast
cancer incidence within a population.
CYP17 codes for an enzyme tht catalyzes two steps in the
synthesis of oestradiol, and work on CYP17 is among the
first of a new generation of studies, looking at whether
common genetic polymorphisms may affect breast cancer
risk by affecting hormone metabolism. Two studies [31,32]
have looked at serum oestradiol concentrations in relation
to a single base pair polymorphism in the promoter region
of  CYP17, which might affect gene transcription; both
studies reported slightly higher oestradiol concentrations in
women with the putatively more active polymorphism.
However, studies of this polymorphism in CYP17 have not
demonstrated a significant elevation in breast cancer risk
[32–36]. Several other mechanisms are also possible: poly-
morphisms in other genes encoding enzymes in the steroid
synthesis and metabolism pathway (CYP11A1, 3b-HSD,
17b-HSD,  CYP19) may affect steroid levels; polymor-
phisms in the genes encoding peptides (prolactin, insulin-
like growth factor-I) may influence the serum
concentration or the intrinsic activity of the hormone; poly-
morphisms in hormone receptor genes [oestrogen receptor
(ER)-a, ER-b] may increase the biological response to a
given hormone level; and polymorphisms in genes encod-
ing hormone-binding proteins [sex hormone binding glob-
ulin (SHBG), insulin-like growth factor binding protein 3]
could affect risk by altering hormone bioavailability.
Testing these hypotheses in large epidemiological studies
is now technically straightforward and significant polymor-
phisms are likely to be identified in the near future.
What about environmental determinants of endogenous
hormone levels, such as diet and exercise? Despite bur-
geoning interest in the effects of diet on both hormones
and breast cancer, the only established link is with
obesity. In postmenopausal women, obesity causes a
substantial increase in bioavailable oestradiol due to
increased production from androstenedione and oestrone
and a decrease in SHBG [37], and obese postmenopausal
women have about a two-fold increased risk for breast
cancer. More data from prospective studies are needed to
show whether the effect of obesity on breast cancer risk
can be explained by its effects on oestradiol, but it is
already clear that breast cancer rates could be reduced by
reducing the prevalence of obesity in postmenopausal
women [38]. The possible protective effect of exercise is
less firmly established, but moderate exercise in young
women might perhaps reduce breast cancer risk by reduc-
ing exposure to both oestradiol and progesterone [39].
Hypotheses by which nutrition could affect oestradiol
metabolism abound. For example, fat might increase syn-
thesis, fibre might increase excretion, phyto-oestrogens
might block the stimulation of receptors, and indoles
might accelerate catabolism. None of these hypotheses
has yet been strongly supported, and perhaps the most
promising current hypothesis is that alcohol may increase
breast cancer risk by increasing endogenous oestradiol
levels [40,41]. Establishing the effects of diet on hormone
metabolism is important, because studies of migrants
show that increases in breast cancer risk can be observed
as soon as 10 years after migrating from East Asia to the
USA [42]. Japanese women living in rural Japan have
much lower serum oestrogen levels than white Americans,
but Japanese-Americans now have serum oestrogen levels
as high as white Americans [43]. The increases in oestro-
gen levels and breast cancer risk may both be determined
by the ‘westernization’ of diet.
The evidence that oestradiol is an important determinant
of breast cancer risk is now strong. Research during the
next few years may be expected to confirm the impor-
tance of oestradiol, to clarify the roles of other hormones,
and to establish the environmental and genetic determi-
nants of endogenous hormone levels.
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